1 Novel Tools for the Detection of Active TB and Drug Resistance TB Diagnostics Symposium Ontario Agency for Health Protection and Promotion Toronto, Ontario October 8 th, 2009 Jessica Minion, MD PGY-5 Medical Microbiology MSc Epidemiology McGill University, Montreal, QC
2 Global TB Case Detection 2.6 million new smear + cases notified in % of the estimated 4.1 million cases 5.3 million new cases overall notified in % of the estimated 9.3 million cases WHO Report 2009 Global Tuberculosis Control
4 Microscopy 1882 Culture 1882 Chest X-ray 1896
5 Thanks to a resurgence of interest (along with massive funding)
6 ... and advances in basic science Omics (genomics, proteomics, etc) Immunology Molecular Biology Biotechnology Nanotechnology
7 There is now a promising diagnostics pipeline Pai et al. Sem Resp Crit Care Med 2008
8 Technology needs for Patient-Centered Care Reference Lab Surveillance Regional Lab 5 % Fraction of patients seen Faster than solid culture 10 % LJ - 40d Auto. LC 15d Manual 15d LPA 1d More sensitive than microscopy Peripheral Lab 25 % Smear - 60% LED +10% Manual NAAT +25% Auto NAAT +40% Clinic / Health Post Simpler than microscopy 60 % Symptoms AG/AB Molecular VOC Source: Foundation for Innovative New Diagnostics (FIND)
9 NEW TECHNOLOGIES
10 Smear Microscopy Simple, cheap High specificity Poor sensitivity Especially with HIV coinfection Especially with extrapulmonary TB
12 New Policies on Smear Microscopy Front Loaded Specimen Collection? Sputum Processing? LED Fluorescent Microscopy? 2009
13 Fluorescent LED Microscopy Higher Sensitivity than ZN (and possibly conventional FM) 46% time savings vs. ZN (equivalent to conventional FM) Advantages of FM but less expensive, requires less maintenance, no need for a dark room Minion et al. unpublished
14 Commercial LED Microscopes Minion et al. Exp Rev Med Dev 2009
15 Challenges for current EQA program 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% month 0 month 1 month 2 month 3 month 4 month 5 Current External Lab QA program involves sending selected slides into SNRL for rechecking quarterly 3+ pos 2+ pos 1+ pos scant + ABS 100% Auramine-stained slides will be faded and unreliable % Initially Positive Slides Read Positive 90% 80% 70% 60% 50% 40% 30% 20% 10% RT_month INC_month FRG_month Minion, et al. unpublished 0% month 0 month 1 month 2 month 3 month 4 month 5
16 Other Potential Innovations
17 Culture High Sensitivity Slow Turnaround Time, Expensive, Biosafety concerns Push towards liquid culture systems Partly driven by HIV epidemic Improves some problems while exacerbating others
18 New Policies on Culture-based Diagnostics 2007
20 New Policies on Culture-based Diagnostics MODS? TLA? NRA? 2009 CRI? Phage?
21 Microscopically Observed Drug Susceptibility (MODS) Direct inoculation of patient specimens detection & DST Liquid culture more sensitive than LJ Microcolony detection faster turnaround time Biosafety? Specificity of ID?
22 Thin Layer Agar (TLA) Direct inoculation of patient specimens detection & DST Solid media easier to manipulate Microcolony detection faster turnaround time Biosafety? Specificity of ID?
23 Nitrate Reductase Assay (NRA) Based on MTB s ability to reduce nitrate to nitrite Simple Sensitive detection of small amount of metabolic biproduct improves turnaround time Prevalence of nitrate reductase negative strains of MTB? KNO 3 - containing media Add reagent to drug-free slant day 7 (repeat day 10, 14) Color development = growth
24 Colorimetric Redox Indicators (CRI) Based on reduction of indicator by growing MTB MIC determination using microdilution Detection of active metabolism improves turnaround time Biosafety concerns? Suitable for reference labs? Incubate microdilution plate 7 days Add indicator to all wells, incubate overnight Color change = growth
25 Mycobacteriophage Assays (FASTPlaque TM ) Based on amplification of phage viruses in live MTB 2 day turnaround for detection & DST Minimal biosafety concerns BUT... High rates of contaminated or uninterpretable tests High rate of false positives
26 GRADE Summary Table Novel Culture Methods Diagnostic (Reference) # Studies (# Participants) Pooled Accuracy Estimates from Meta-Analyses Turnaround Time Contamination Rates Quality of Evidence Costs Resources Sens Spec MODS (1) 9 studies (1474 participants) days 6.3% Moderate Equipment: ++ Consumables: ++ Training: extensive Infrastructure: ++/+++ TLA (1) 3 studies ( days 11.8% Low Equipment: + Training: extensive participants) Consumables: ++ Infrastructure: ++/+++ Phage 12 studies FASTPlaque (2) (2945 participants) CRI (3) 31 studies (2498 participants) NRA (4) 19 studies (2304 participants) WHO-endorsed rapid test for DST (for comparison) days 20.4% Very Low Equipment: ++ Consumables: days 5% Moderate Equipment: + Consumables: days 4.8% Moderate Equipment: + Consumables: ++ Training: moderate Infrastructure: ++/+++ Training: extensive Infrastructure: +++ Training: moderate Infrastructure: ++/+++ LPA (5) 12 studies (4937 participants) days Moderate Equipment: +++ Consumables: +++ Training: moderate Infrastructure: ++/+++ Minion et al. unpublished
28 NAAT High specificity and PPV Sensitivity is lower and highly variable Especially in extrapulmonary Especially in smear negative reduced utility in HIV + Expensive limited applicability in developing countries
30 2009 Updated CDC Guidelines
31 Line Probe Assays Detection of MTB & RIFresistance (rpob) Requires extraction, amplification Colorimetric development using immobilized probes Inno-LiPA Rif.TB assay Innogenetics, Belgium Expensive Feasible in peripheral settings? GenoType MTBDRplus assay Hain Lifescience GmbH, Germany
32 New Policy on Line Probe Assays 2008
33 New Initiatives to Expand Access
34 Loop Mediated Isothermal Amplification (LAMP) Simplified NAAT, does not require a thermocycler, detection by fluorescence Rapid (1 hour) High throughput Sensitivity 97%, Specificity 99% (culture reference) Feasible in high burden settings? Eiken Chemical Co., Tokyo, Japan
36 Serology Attractive... especially if point of care (POC) option >80 antigenic targets evaluated and several commercial assays developed All existing serologic tests have failed to demonstrate adequate accuracy Although still marketed and sold by many companies and used in developing countries! Thorax 2007 PLoS Medicine 2007 Clin Vaccine Immunol 2009
37 WHO/TDR evaluation of 19 commercial serologic tests for TB: poor accuracy WHO/TDR Diagnostics Evaluation Series 2009
38 Antigen Detection Urinary Lipoarabinomannan (LAM) ELISA-based test Clearview (R) TB (Inverness, UK) Optimal specimen, rapid turnaround (2.5 hrs) Potential for POC dipstick Initially evaluations were promising Boehme et al. 2005: 80% sensitivity; 99% specificity BUT... Subsequent studies have failed to demonstrate similar performance Indicated for HIV+? Improved sensitivity with low CD4?
39 Disappointing LAM performance Minion et al. Unpublished
40 Challenges for diagnostic research Avoiding Optimism Bias Inappropriate study designs Inappropriate study populations Transferability and Reliability Selective reporting of results Unjustified positive conclusions Publication Bias Rapid licencing, commercialization and marketing of tests before adequate evaluation
41 If exposure and disease are not associated False positive study Hot topic Bias Publication Bias 100 studies will be designed If = 0.05 THE FALSE POSITIVE RESEARCH CYCLE (Choi, 1998) 5 studies show false positive results Positive results bias 5 studies will be published Likely to be meta-analyzed Editor s bias Courtesy: Bernard Choi, PHAC
42 Challenges for diagnostic research Ensuring Quality Bias due to inappropriate reference standards Spectrum bias Verification bias Partial verification Differential verification Review bias (lack of blinding) Incorporation bias
43 Reporting Standards & Quality Assessment Tools
44 Challenges for diagnostic research Moving Beyond Accuracy accuracy is a surrogate for patientimportant outcomes Results in low quality evidence for policy recommendations
45 Blueprint for new diagnostics development Demonstration of test accuracy will not be enough Stop TB Partnership s New Diagnostic Working Group 2009
46 Stop TB Research Movement Landscape of TB Diagnostic Research: PRELIMINARY RESULTS Majority of TB diagnostic studies are focused on accuracy Abstracts included in the preliminary results 3922 Abstracts available 3230 (82%) Original Study 3129 (97%) Abstracts excluded: No abstract available 692 (18%) Abstracts excluded: Not original study 101 (3%) 1. Underpinning Research 302 (10%) 2. Aetiology 1028 (33%) 3. Prevention of Disease and Conditions, and Promotion of Well-Being 120 (4%) 4. Detection, Screening and Diagnosis 420 (13%) 5. Development 6. Evaluation of 8. Health and 7. Management of Treatments Treatments and Social Care Of Diseases and Therapeutic Therapeutic Services and Conditions Interventions Interventions Research 232 (7%) 202 (7%) 162 (5%) 104 (3%) 9. Case Reports or Case Series 559 (18%) 1.1Biological 272 (91%) 1.2 Psycological, Socioeconomic 0 (0%) 1.3 Chemical, Physical 0 (0%) 1.4 Methodology 23 (8%) 1.5 Ressources 3 (1%) 2.1 Biological 319 (31%) 2.2 Environmental 195 (19%) 2.3 Psychological, social, economic 65 (6%) 2.4 Distribution 402 (39%) 2.5 methodology 49 (5%) 2.6 Ressources 2 (0.2%) 3.1 Behaviour 0 (0%) 3.2 Environmental 11 (9%) 3.3 Nutrition, Chemoprevention 0 (0%) 3.4 Vaccines 109 (91%) 3.5 Ressources 0 (0%) 4.1 Preclinical 32 (8%) 4.2 Evaluation 372 (89%) 4.3 Impact 4 (1%) 4.4 Population Screening 2 (0.5%) 4.5 Resources 2 (0.5%) 4.6 Cost 8 (2%) 7.1 Individual care needs 96 (41%) 7.2 End of life Care 1 (1%) 7.3 Management 133 (57%) 7.4 Ressources 2 (1%) 8.1 Organisation Delivery of Services 54 (52%) 8.2 Health, welfare Economics 15 (14%) 8.3 Policy, ethics Research Governance 34 (33%) 8.4 Methodology 1 (1%) 8.5 Ressources 0 (0%)
47 In conclusion, much progress has been made in improving diagnosis but...
48 Are we close to the big goal of a simple point of care test?
49 What specifications should a POC test for TB have?
50 Revolution through competition!
51 Revolution through competition! X Prize May be Announced for a TB Diagnostic Test!
52 Acknowledgements Madhukar Pai Fran Jaimeson Shana Kelley
INTERNATIONAL STANDARDS FOR Tuberculosis Care diagnosis treatment public health 3rd edition, 2014 Developed by TB CARE I with funding by the United States Agency for International Development (USAID) TB
Out of Step Deadly implementation gaps in the TB response A survey of TB diagnostic and treatment practices in eight countries October 2014 www.msfaccess.org About Médecins Sans Frontières (MSF) MSF is
formerly the Center for Biosecurity Diagnosing Infection at the Point of Care How Standards and Market Forces Will Shape the Landscape for Emerging Diagnostic Technologies Final Report June 2013 UPMC Center
Prevention and Control Methicillin-Resistant Staphylococcus aureus (MRSA) National Clinical Guideline No. 2 December 2013 Guideline Development Group The Prevention and Control of Methicillin-resistant
Data for Individual Health Prepared for: Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. JSR-14-TASK-007 Prepared by: JASON The MITRE Corporation
Putting HIV Treatment to the Test A Product Guide for Viral Load and Point-of-Care CD4 Diagnostic Tools www.msfaccess.org THE MSF ACCESS CAMPAIGN In 1999, on the heels of Médecins Sans Frontières (MSF)
WHO/NMH/MNC/03.1 Original: English Screening for Type 2 Diabetes Report of a World Health Organization and International Diabetes Federation meeting World Health Organization Department of Noncommunicable
Waste and Inefficiency in the U.S. Health Care System Clinical Care: A Comprehensive Analysis in Support of System-wide Improvements ABOUT NEHI The New England Healthcare Institute (NEHI) is an independent,
FDA Report FDA ACTION PLAN TO ENHANCE THE COLLECTION AND AVAILABILITY OF DEMOGRAPHIC SUBGROUP DATA August 2014 Table of Contents Introduction and Background... 1 FDA Action Plan to Enhance the Collection
Same-day diagnosis of tuberculosis by microscopy Policy statement WHO Library Cataloguing-in-Publication Data Same-day diagnosis of tuberculosis by microscopy: policy statement. 1.Tuberculosis, Pulmonary
Clinical Decision Support Systems: State of the Art Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov
universal access to malaria diagnostic testing AN OPERATIONAL MANUAL Universal access to malaria diagnostic testing An operational manual i WHO Library Cataloguing-in-Publication Data: Universal access
Clostridium difficile infection in Europe A CDI Europe Report CONTENTS FOREWORD 5 1. INTRODUCTION: CDI WHAT IS THE PROBLEM? 6 1.1 How does CDI occur? 6 1.2 How common is CDI? 8 1.3 Who is at risk of CDI?
INVESTING IN HEALTH Commission Staff Working Document Social Investment Package February 2013 Health and Consumers Introduction This document complements the Commission Communication Towards Social Investment
BD Newsletter June 2001 Volume 12 No. 2 Indispensable to human health Lab O MICROBIOLOGY NEWS & IDEAS In This Issue... TechniTopic: Update on Pertussis and Pertussis-like Organisms 3 BACTEC System News:
Strategic Review of Health and Medical Research in Australia CONSULTATION PAPER SUMMARY Issues and Proposed Recommendations Draft for Public Comment 3 October 2012 This is a summary document that necessarily
EN HORIZON 2020 WORK PROGRAMME 2014 2015 4. Revised This Work Programme was adopted on 10 December 2013. The parts that relate to 2015 (topics, dates, budget) have, with this revised version, been updated.
Epidemiol. Infect., Page 1 of 9. f 26 Cambridge University Press doi:1.117/s95268866935 Printed in the United Kingdom Type 2 diabetes and tuberculosis in a dynamic bi-national border population B. I. RESTREPO
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September
Evidence Report/Technology Assessment Number 160 Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and
Biologics and biosimilars An overview Contents An introduction to biotechnology... 3 A brief history of medicine development... 4 What are biologic medicines?... 5 How are biologic medicines developed?...
FEDERAL HEALTH IT STRATEGIC PLAN 2015 2020 Prepared by: The Office of the National Coordinator for Health Information Technology (ONC) Office of the Secretary, United States Department of Health and Human
Early detection of HIV infection in infants and children Guidance note on the selection of technology for the early diagnosis of HIV in infants and children Summary of recommendations Because of the high